Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

PHASE3TerminatedINTERVENTIONAL
Enrollment

5,364

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

June 30, 2010

Conditions
AtherosclerosisAcute Coronary Syndrome (ACS)
Interventions
DRUG

Cangrelor

cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)

DRUG

clopidogrel

clopidogrel capsules (600 mg) at end of PCI

DRUG

Placebo bolus & placebo infusion

placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)

DRUG

Placebo capsules - end of PCI

Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing

DRUG

Placebo capsules - end of infusion

Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing

Trial Locations (1)

58104

Innovis Health, Fargo

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY

NCT00385138 - Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. | Biotech Hunter | Biotech Hunter